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Background
While malaria transmission is falling in many areas due
to increased use of bed-nets and anti-malarials, it
remains an enormous burden [1]. The leading malaria
vaccine candidate, RTS,S, results in often considerably
less than 60% efficacy against clinical malaria [2] result-
ing in a need for other approaches that may enhance
this partial protection. One such approach is the use of
viral vectors in a heterologous prime-boost regime with
the aim of inducing a T-cell response. Previous studies
have shown high levels of immunogenicity by using a
chimpanzee adenovirus (ChAd63) followed by an atte-
nuated vaccinia virus (modified vaccinia Ankara (MVA))
to deliver the pre-erythrocytic antigen, multiple epitope
string with thrombospondin-related adhesion protein
(ME-TRAP) [3].
Materials and methods
We undertook a phase IIb study to assess the efficacy
and further evaluate the immunogenicity and safety of
such a vaccination strategy involving 120 healthy adults
in Dakar, Senegal. Volunteers received either ChAd63
followed by MVA, both containing ME-TRAP, or two
shots of rabies vaccine. After the second immunization,
all volunteers were given short-lasting antimalarials. The
time taken to first malaria infection was measured by
PCR and compared between the two groups. IFN-g pro-
duction by T-cells, seen as an integral component of
liver stage protection, was measured by ELISpot at var-
ious points throughout the trial. Intracellular cytokine
staining was used to determine the relative proportions
of CD4+ and CD8+ T-cells secreting IL-2, IFN-g and/or
TNFa in response to peptide stimulation.
Results
Peak immunogenicity was identified 7 days after boosting
vaccination with MVA ME-TRAP, at a geometric mean
of 1266 spots per million PBMC (95% CI 985-1504) com-
pared with 87 spots per million (95% CI 57-117) among
control vaccinees, P < 0.0001. While this vaccine strategy
is aimed at enhancing the cellular response towards the
liver stage, TRAP-specific IgG responses were also mea-
sured by ELISA and were modest in magnitude. Efficacy
analysis using time to PCR positive is ongoing, however
this vaccine approach has shown an acceptable safety
profile and good, potent cellular immunogenicity in this
semi-immune population.
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